Investigation Report on China Tiotropium Bromide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||297269|
|出版日期||內容資訊||英文 20 Pages
|中國的Tiotropium bromide市場分析 Investigation Report on China Tiotropium Bromide Market, 2010-2019|
|出版日期: 2015年06月04日||內容資訊: 英文 20 Pages||
和全球各國同樣，中國大氣污染也惡化了，氣喘和慢性阻塞性肺病（COPD）的患者數增加，因此擴大了相關治療藥的市場機會。Boehringer Ingelheim Group開發的使用Tiotropium bromide的治療藥「Spiriva」，2002年6月受荷蘭、菲律賓認可，中國也在2006年受認可。該產品的銷售額在全球2013年到達了近50億美元。還有調查對象的醫院用Tiotropium bromide的銷售額，在2006∼2014年之間，以年複合成長率90％推移，達到了1,400萬元。今後由於產業發展和環境問題的解決延遲，氣喘、慢性阻塞性肺病的患者數持續增加，一般預期Tiotropium bromide的市場規模也將持續擴大。
In recent years, various allergic diseases demonstrate an increasing trend under the influence of global environmental changes, leading to the occurrence of seasonal cough and asthma in winter and spring. Affected by tobacco, dust and pollutants, the incidence of chronic obstructive pulmonary disease (COPD) is still on the rise. COPD is a chronic pulmonary disease characterized by incompletely reversible airflow obstruction. The major clinical manifestations are recurrent cough, expectoration, dyspnea. COPD often demonstrate a progressive characteristic, including large parts of chronic bronchitis and emphysema.
According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003-2033.
For many years, the COPD market and anti-asthmatic agents market have been dominated by four big companies - GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.
Tiotropium bromide, a long-acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD's clinical course so as to help improve the state of patient's life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.
According to CRI's survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006-2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.
It is expected that in the next few years, tiotropium bromide market in China will keep expanding fast.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: